MeiraGTx Enters into a Strategic Collaboration with Hologen AI to Expedite Phase 3 Development of AAV-GAD for Parkinson's Disease and Industrialize MeiraGTx's Proprietary Manufacturing Process

Core Viewpoint - MeiraGTx Holdings plc has announced a strategic collaboration with Hologen Limited, which includes a $200 million upfront cash payment and the formation of a joint venture, Hologen Neuro AI Ltd, aimed at developing therapies for neurodegenerative diseases, particularly Parkinson's disease [1][2][10]. Financial Aspects - MeiraGTx will receive$200 million in upfront cash at closing [2][10] - Hologen will provide up to $230 million in committed capital to fund the development of AAV-GAD for Parkinson's disease and other CNS programs [2][6] - The collaboration is expected to extend MeiraGTx's cash runway and support its internal manufacturing capabilities [7] Joint Venture Details - The joint venture, Hologen Neuro AI Ltd, will be co-owned, with MeiraGTx retaining 30% ownership and leading clinical development and manufacturing [3][10] - Hologen will contribute its generative AI technology to optimize MeiraGTx's manufacturing processes [3][10] - The joint venture will focus on the development of AAV-GAD and other locally delivered CNS genetic medicines [6][10] Clinical Development - MeiraGTx's AAV-GAD program for Parkinson's disease is Phase 3 ready, with positive data reported from a clinical bridging study showing significant improvements in patient outcomes [4][10] - The collaboration aims to enhance the robustness and efficiency of the AAV-GAD Phase 3 clinical study using Hologen's AI technology [5][7] Company Background - MeiraGTx is a clinical-stage genetic medicines company with a broad pipeline, including four late-stage clinical programs targeting various diseases [9] - The company has developed advanced manufacturing capabilities and innovative technologies for gene therapy, including a novel riboswitch gene regulation technology [9]